Androulakis G, Panoysis P A
Second Surgical Clinic, University of Athens, Greece.
Angiology. 1989 Jan;40(1):1-4. doi: 10.1177/000331978904000101.
Sixty patients with varicose veins, in the age range 25 to 52 years, entered the trial and were divided by random allocation into 2 equal groups. The first group received calcium dobesilate orally in dosage of 750 mg daily while the second remained untreated. Out of 25 patients who completed the 3-month treatment course, clinical improvement occurred in 19 (76%). Mercury strain gauge plethysmography in those 19 patients showed a statistically significant mean fall in the venous distensibility index, in maximum venous outflow and in the capillary filtration coefficient after the course of calcium dobesilate. The mean erythrocyte sedimentation rate in the 25 patients fell from 40 mm in 1 hour (Westergren) before treatment to 10 mm at the end of the course. In 42% of the patients there was a fall in serum globulin concentration and correction of the albumin/globulin ratio and in 35% there was a slight fall in serum fibrinogen concentration. Possibly calcium dobesilate's known action in lowering blood viscosity contributes to its beneficial effect in varicose veins.
60例年龄在25至52岁之间的静脉曲张患者进入试验，并通过随机分配分为2个相等的组。第一组每天口服750毫克剂量的羟苯磺酸钙，而第二组不接受治疗。在完成3个月治疗疗程的25例患者中，19例（76%）出现了临床改善。在这19例患者中，汞应变计体积描记法显示，在接受羟苯磺酸钙疗程后，静脉扩张指数、最大静脉流出量和毛细血管滤过系数的平均下降具有统计学意义。25例患者的平均红细胞沉降率从治疗前1小时40毫米（魏氏法）降至疗程结束时的10毫米。42%的患者血清球蛋白浓度下降，白蛋白/球蛋白比值得到纠正，35%的患者血清纤维蛋白原浓度略有下降。羟苯磺酸钙降低血液粘度的已知作用可能有助于其对静脉曲张的有益作用。
